CT Lung Screening

Low-dose CT chest examination for early detection of lung nodules and lung cancer in current or former smokers and high-risk individuals. No contrast injection required. GE Revolution GSI CT with low-dose protocol. Radiologist report with pulmonary nodule assessment and follow-up guidance.

Affidea Praha's low-dose CT lung screening uses the GE Revolution GSI CT scanner with dedicated dose-reduction protocols to examine the lungs, airways, pleura, and adjacent mediastinal structures with a radiation dose substantially lower than a standard diagnostic chest CT. The examination requires no contrast injection, no fasting, and takes only a few minutes in the scanner — a brief breath-hold of approximately ten seconds during image acquisition. Lung cancer is the leading cause of cancer death in Europe, largely because most cases are diagnosed at an advanced, incurable stage. Annual low-dose CT screening in appropriately selected high-risk individuals is supported by large prospective randomised controlled trials — the US National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality with annual CT screening compared to chest radiography, and the Dutch-Belgian NELSON trial confirmed similar mortality benefit. European guidelines (ESR, ESTS, ERS, ESTRO) now endorse annual LDCT screening for individuals aged 50–75 who have smoked at least 20 pack-years and either currently smoke or quit within the past 15 years. Beyond the primary lung evaluation, the radiologist systematically reviews the mediastinum for lymphadenopathy and masses, the heart and pericardium for incidental findings, the visible liver, kidneys, and adrenal glands, and the thoracic spine for vertebral abnormalities. Pulmonary nodules are characterised by size, density, and morphology, with follow-up recommendations based on international guidelines (Fleischner Society, Lung-RADS) that specify the appropriate interval for follow-up imaging based on nodule risk profile. The written report includes a structured assessment of all findings and explicit guidance on any required follow-up. Annual repeat screening is recommended for individuals who remain within the eligible risk category.